Gilead Sciences Inc. signaled its continuing push into cancer immunotherapy by inking a deal with Agenus Inc. to develop and commercialize up to five novel immuno-oncology treatments, an arrangement potentially worth more than $1.8bn for the Lexington, Massachusetts-based biotech.
For Gilead, the R&D pact with immunotherapy specialist Agenus is its latest effort to enter the oncology field and help...








